Benzinga | Nov 17, 2021 08:29AM EST

Barclays Maintains Overweight on Prelude Therapeutics, Lowers Price Target to $20

Barclays analyst Peter Lawson maintains Prelude Therapeutics (NASDAQ:PRLD) with a Overweight and lowers the price target from $33 to $20.